United Therapeutics (UTHR) Income from Discontinued Operations (2010 - 2011)
United Therapeutics (UTHR) reported Income from Discontinued Operations of 69000.0 for Q3 2011, up 82.31% on a YoY basis from 37848.1 in Q3 2010, and down 246.81% sequentially from 47000.0 in Q2 2011.
United Therapeutics (UTHR) Income from Discontinued Operations (2010 - 2011) Analysis & Trends
United Therapeutics (UTHR) has 2 years of Income from Discontinued Operations data on file, last reported at 69000.0 in Q3 2011.
- For the quarter ending Q3 2011, Income from Discontinued Operations rose 82.31% year-over-year to 69000.0; the trailing twelve-month figure through Dec 2011 stood at 7000.0 (changed N/A YoY), and the FY2011 full-year result was 7000.0, up 100.13% from the prior year.
- Income from Discontinued Operations retreated to 69000.0 in Q3 2011, from 47000.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of 47000.0 in Q2 2011 to a low of 4634000.0 in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | -69,000.00 |
| Jun 30, 2011 | 47,000.00 |
| Mar 31, 2011 | 29,000.00 |
| Dec 31, 2010 | -4.63 Mn |
| Sep 30, 2010 | -390,000.00 |
| Jun 30, 2010 | -259,000.00 |